The governing body of the Cancer Prevention and Research Institute of Texas (CPRIT) has approved $63 million in grants that illustrate the agency’s reach not only in Texas but around the world.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
